Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4842406 | 0.99 | CCR3 (0.45) | CCR3ACHEBACE1BCHE | |
| SCHEMBL4206936 | 0.90 | ACHE (0.46) | CCR3ACHE | |
| Hydrochloric Acid SCHEMBL4203851 | 0.89 | ACHE (0.46) | CCR3ACHEBCHE | |
| SCHEMBL4209827 | 0.88 | ACHE (0.45) | CCR3ACHE | |
| Hydrochloric Acid SCHEMBL4207910 | 0.87 | ACHE (0.44) | CCR3ACHEBCHE | |
| SCHEMBL4203807 | 0.78 | ACHE (0.44) | CCR3ACHE | |
| SCHEMBL12520345 | 0.78 | ACHE (0.31) | ACHE | |
| SCHEMBL3849440 | 0.78 | ACHE (0.42) | ACHEBACE1BCHE | |
| SCHEMBL4206058 | 0.77 | ACHE (0.43) | CCR3ACHE | |
| SCHEMBL20214251 | 0.76 | CCR3 (0.59) | CCR3ACHEBACE1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841739-B1 | PROCESS FOR PRODUCING 1-BENZYL-4-[(5,6-DIMETHOXY-1-INDANON-2-YL)METHYL] PIPERIDINE OR SALT THEREOF VIA NOVEL INTERMEDIATE | JUBILANT ORGANOSYS LTD (IN) | 2013-02-20 | — | — | EP | claimed |
| US-8124783-B2 | Process for producing 1-benzyl-4-[5,6-dimethoxy-1-indanon-2-yl)methyl] piperidine or its salt thereof via novel intermediate | JUBILANT ORGANOSYS LIMITED (IN) | 2012-02-28 | — | — | US | claimed |
| US-20090137812-A1 | PROCESS FOR PRODUCING 1-BENZYL-4-[5,6-DIMETHOXY-1-INDANON-2-YL)METHYL]PIPERIDINE OR ITS SALT THEREOF VIA NOVEL INTERMEDIATE | JUBILANT ORGANOSYS LIMITED (IN) | 2009-05-28 | — | — | US | claimed |
| EP-1841739-A4 | PROCESS FOR PRODUCING 1-BENZYL-4-[(5,6-DIMETHOXY-1-INDANON2-YL)METHYL] PIPERIDINE OR ITS SALT THEREOF VIA NOVEL INTERMEDIATE | JUBILANT ORGANOSYS LTD (IN) | 2008-10-01 | — | — | EP | claimed |
| EP-1841739-A1 | PROCESS FOR PRODUCING 1-BENZYL-4-[(5,6-DIMETHOXY-1-INDANON2-YL)METHYL] PIPERIDINE OR ITS SALT THEREOF VIA NOVEL INTERMEDIATE | Jubilant Organosys Limited (IN) | 2007-10-10 | — | — | EP | claimed |
| WO-2006070396-A1 | PROCESS FOR PRODUCING 1-BENZYL-4-[(5,6-DIMETHOXY-1-INDANON2-YL)METHYL] PIPERIDINE OR ITS SALT THEREOF VIA NOVEL INTERMEDIATE | JUBILANT ORGANOSYS LIMITED (IN) | 2006-07-06 | — | — | WO | claimed |
| EP-1654230-A1 | PREPARATION OF INTERMEDIATES FOR ACETYL CHOLINESTERASE INHIBITORS | Hetero Drugs Limited (IN) | 2006-05-10 | — | — | EP | claimed |
| US-20060041140-A1 | 5,6-dimethoxy-2-(4-pyridyl)methyl-1-indanone is hydrogenated using platinum oxide catalyst in the presence of hydrochloric acid under a pressure of 2 bars to give 4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride | HETERO DRUGS LIMITED (IN) | 2006-02-23 | — | — | US | claimed |
| WO-2005076749-A2 | A NOVEL PROCESS FOR THE PREPARATION OF 1-BENZYL-4-[(5,6-DIMETHOXY-1-INDANON-2-YL)METHYL]PIPERIDINE | JUBILANT ORGANOSYS LIMITED (IN) | 2005-08-25 | — | — | WO | claimed |
| WO-2005003092-A1 | PREPARATION OF INTERMEDIATES FOR ACETYL CHOLINESTERASE INHIBITORS | HETERO DRUGS LIMITED (IN) | 2005-01-13 | — | — | WO | claimed |
| WO-1998056250-A1 | METHOD FOR REDUCING SIDE EFFECTS | ALCON LABORATORIES, INC. (US) | 1998-12-17 | — | — | WO | claimed |
| WO-1998056249-A1 | METHOD FOR ENHANCING THE ACTIVITY OF GLAUCOMA DRUGS | ALCON LABORATORIES, INC. (US) | 1998-12-17 | — | — | WO | claimed |
| WO-1998056379-A1 | COMPOSITIONS AND METHODS FOR TREATING GLAUCOMA | ALCON LABORATORIES, INC. (US) | 1998-12-17 | — | — | WO | claimed |
| WO-1998056380-A1 | METHOD TO REVERSE MYDRIASIS | ALCON LABORATORIES, INC. (US) | 1998-12-17 | — | — | WO | claimed |
| EP-4413977-A1 | METHOD FOR PREPARING MICROPARTICLES CONTAINING POORLY SOLUBLE DRUGS | Inventage Lab Inc. (KR) | 2024-08-14 | — | — | EP | disclosed |
| CN-118234488-A | Process for producing microparticles containing poorly soluble drug | 创技公司株式会社 | 2024-06-21 | — | — | CN | disclosed |
| US-20240180896-A1 | METHOD FOR PREPARING MICROPARTICLES CONTAINING POORLY SOLUBLE DRUGS | INVENTAGE LAB INC. (KR) | 2024-06-06 | — | — | US | disclosed |
| WO-1998056250-A1 | METHOD FOR REDUCING SIDE EFFECTS | ALCON LABORATORIES, INC. (US) | 1998-12-17 | — | — | WO | disclosed |
| WO-1998056249-A1 | METHOD FOR ENHANCING THE ACTIVITY OF GLAUCOMA DRUGS | ALCON LABORATORIES, INC. (US) | 1998-12-17 | — | — | WO | disclosed |
| WO-1998048785-A2 | ALLELIC POLYGENE DIAGNOSIS OF REWARD DEFICIENCY SYNDROME AND TREATMENT | KENNETH BLUM, INC. (US) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137812-A1 | PROCESS FOR PRODUCING 1-BENZYL-4-[5,6-DIMETHOXY-1-INDANON-2-YL)METHYL]PIPERIDINE OR ITS SALT THEREOF VIA NOVEL INTERMEDIATE | TET2, DHPS, AZI2 | CCR3 4746/4885ACHE 2994/4885BACE1 2856/4885 |
| US-20240180896-A1 | METHOD FOR PREPARING MICROPARTICLES CONTAINING POORLY SOLUBLE DRUGS | CHMP4B, GP6, ALB | CCR3 2467/4885ACHE 3367/4885BACE1 4388/4885 |
| US-20060041140-A1 | 5,6-dimethoxy-2-(4-pyridyl)methyl-1-indanone is hydrogenated using platinum oxide catalyst in the presence of hydrochloric acid under a pressure of 2 bars to give 4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride | ACHE, IDH2, IMPDH2 | CCR3 4712/4885ACHE 1/4885BACE1 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.